TUKYSA 50 MG
TUCATINIB : 50 MG · DIN 02499827 · SEAGEN INC.
Health Canada status: MARKETED
What is TUKYSA?
TUKYSA 50 MG contains TUCATINIB : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02499827, held by SEAGEN INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TUKYSA used for?
In combination with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases, after prior trastuzumab, pertuzumab, and trastuzumab emtansine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02499827 |
|---|---|
| Brand name | TUKYSA |
| Generic / active ingredient | TUCATINIB : 50 MG |
| Manufacturer | SEAGEN INC. |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EH03 TUCATINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Nov-2025 |
| Original market date | 2020-10-08 00:00:00 |
How is it administered?
300 mg (two 150 mg tablets) orally twice daily in combination with trastuzumab and capecitabine. Swallow whole; do not chew, crush, or split. Take ~12 hours apart.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text sections (Section 11 header present but content truncated).
How is it supplied?
50 mg and 150 mg tablets (specific bottle counts not provided in text, but described as round/oval yellow film-coated tablets).
Contraindications
Hypersensitivity to tucatinib or any ingredient in the formulation. Refer to capecitabine and trastuzumab monographs for their specific contraindications.
Warnings and precautions
Severe diarrhea (can lead to death); severe hepatotoxicity (monitor ALT/AST/bilirubin); embryo-fetal toxicity; palmar-plantar erythrodysesthesia; stomatitis.
What can be used instead?
Other Canadian products sharing ATC code L01EH03 TUCATINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TUKYSA | 150 MG | TABLET | SEAGEN INC. | MARKETED | DIN 02499835 |
Who else supplies TUCATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TUCATINIB appears in 19 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.